Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy

Updated recommendations, the first since 2011

Sponsoring Organizations: American College of Cardiology; American Heart Association

Background and Objective

Our knowledge of the appropriate diagnostic and therapeutic approach to hypertrophic cardiomyopathy (HCM) has evolved over the last decade. The recommendations highlighted below are class 1 (strong) unless noted otherwise.

Key Points

Shared decision making, in which clinicians and individuals with HCM discuss the risks and benefits of diagnostic testing and therapies, is emphasized.
Referral of affected individuals for multidisciplinary care is reasonable (class 2a).
In addition to a history and physical examination, echocardiography is considered central to assess severity of hypertrophy, presence of dynamic left ventricular (LV) outflow…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)